Form 4: Quest Diagnostics SVP Boosts Stake via DRIP

Quest Diagnostics SVP & Chief Commercial Officer Mark E. Delaney acquired 15 shares of common stock through a dividend reinvestment plan.

Summary

• Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics Inc. (DGX), acquired 15 shares of common stock.
• The transaction occurred on October 21, 2025, at a price of $189.077 per share.
• The shares were acquired pursuant to a dividend reinvestment plan (DRIP) administered by the reporting person's broker.
• This transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but the reporting person chose to report it early on this Form 4.
• Following this acquisition, Mark E. Delaney beneficially owns a total of 7,530 shares of Quest Diagnostics common stock.

Sentiment

Score: 6

Explanation: Slightly positive, as an insider's acquisition of shares, even a small amount, generally indicates confidence in the company. However, the small volume limits its overall impact.

Positives

• An insider, the SVP & Chief Commercial Officer, acquired additional shares, which can signal confidence in the company's future prospects.
• The acquisition was made through a dividend reinvestment plan, indicating a long-term, systematic investment approach by the executive.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This specific insider transaction does not provide broader industry context or trends, as it reflects an individual executive's personal investment activity rather than a corporate strategic move.

Stakeholder Impact

• Shareholders may view this as a minor positive signal of management's confidence in the company's stock, potentially reinforcing their own investment decisions.

Key Dates

Recommendation

The acquisition of 15 shares by an executive, while a positive signal of confidence, is a very small transaction in the context of a large public company. It is not significant enough to warrant a change in investment recommendation, suggesting a 'hold' position remains appropriate based solely on this filing.

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Stock Acquisition, Dividend Reinvestment Plan, Executive Compensation